This phase III trial is comparing the safety and effectiveness of a chemotherapy (cabozantinib) and immunotherapy drug (atezolizumab) combination, with a standard of care chemotherapy drug (sorafenib), in patients with advanced hepatocellular (liver) cancer who have not received prior treatment.
This trial is treating patients with hepatocellular (liver) cancer.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Patients in this trial will be randomised into one of three treatment arms; the experimental arm, active comparator or the exploratory arm. In the experimental arm, patients with advanced hepatocellular cancer (HCC) will be given 40mg of oral cabozantinib daily and a 1200 mg intravenous dose atezolizumab every three weeks. In the comparator arm, patients will receive 400mg of oral sorafenib twice a day. Patients in the exploratory arm will be given 60mg of oral cabozantinib once daily.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More